Market Overview

UPDATE: Canaccord Genuity Raises PT to $71 on BioMarin Pharmaceutical on Upcoming Catalysts

Related BMRN
BioMarin Pharma Crashed This Week, So Why Is This Mega-Bank Still Bullish?
FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
FDA Panel Seen As Bad For BioMarin, Good For Sarepta (Investor's Business Daily)

Canaccord Genuity maintained BioMarin Pharmaceutical (NASDAQ: BMRN) with a Buy rating and raised the price target from $56.00 to $71.00.

Canaccord Genuity commented, "Given that we view 2013 as a key value inflection point for BMRN's pipeline and did not previously include 5 of the 6 drugs (excludes Vimizim) in our valuation, we conducted physician diligence to analyze each clinical program – resulting in positive feedback and representing additional peak worldwide revenue of $1.7B. We are optimistic on upcoming catalysts: P1/2 BMN-701 data (Pompe) in late March (though we assume a 15% probability of success on conservatism given the high bar); BMN-673 data (cancer) at ASCO (May 31-June 4); clinical progress of PEG-PAL for PKU (P3 initiation in Q2); BMN-111 for achondroplasia (P2 initiation in mid-'13); and BMN-190 for Batten (IND filing in H1)."

BioMarin Pharmaceutical closed at $54.84 on Monday.

Latest Ratings for BMRN

Nov 2015Goldman SachsInitiates Coverage onBuy
Nov 2015OppenheimerInitiates Coverage onPerform
Nov 2015OppenheimerInitiates Coverage onPerform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (BMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters